(a) The study was terminated too soon The HINT study suggested that although the addition of nifedipine to routine treatment could be "detrimental" to patients not previously on ,B blockers, the addition of nifedipine to existing treatment with ,B blockers was "beneficial". The trial was ended too early, probably because an interim analysis suggested that the risk of myocardial infarction was greater in patients assigned to nifedipine. The reason for this decision does not appear in the discussion and is poorly documented in the appendix. The analysis only demonstrates the well known fact that an unplanned interim analysis without correction of ot error may produce a significant difference.
(b) Imbalance in the monotherapy groups and the inability of the investigators to differentiate between onset of acute myocardial infarction and unstable angina When the Steering Committee made its decision it had not been informed of the clear imbalance of risk at baseline between the study groups. The authors admit that the onset of myocardial infarction in patients presenting with symptoms of unstable angina is uncertain and that they may have miscalculated by more than six hours. Under clinical conditions the use of enzyme determinations for the diagnosis of myocardial infarction is an inaccurate and, at times, an inconsistent indicator of infarction. The higher incidence of myocardial infarctions in the group assigned to nifedipine monotherapy may be explained by the possible (pre) existence of myocardial infarction; and in these circumstances it would be incorrect to use the term "detrimental".
Indeed, the recent TRENT study on a much larger group of patients with confirmed acute myocardial infarction did not show any "detrimental" effects of nifedipine.l Later in the HINT study it was found that 43 patients had already had an infarction before treatment but these cases were not excluded even though they no longer fulfilled the inclusion criterion for "unstable angina" and the therapeutic aim, "treatment of unstable angina pectoris", could no longer be achieved. The uniformity of all the groups was not examined and a table showing these data should be published so that the comparability of the treatment groups and the individual centres can be checked.
(c) Baseline risk differed considerably in the various treatment groups
The "high baseline risk" of recurrent ischaemia or myocardial infarction within 48 hours was 18% in the nifedipine group and 5%o in the metoprolol group. An attempt was made to overcome this imbalance by logistic regression. Since angiography was not available to assess the severity of the underlying coronary artery disease and there is no information on the distribution of these high risk patients among the participating centres, further analysis of these groups on the basis of equal prior risk and equal prior treatment is indicated.
(d) Nifedipine responders were excluded but metoprolol responders were not Patients taking nifedipine maintenance treatment on admittance were excluded whereas those on f blockade maintenance treatment were not. Both medications were probably prescribed for the same indication and it is likely that the exclusion of patients on nifedipine maintenance treatment probably unbalanced the study in favour of metoprolol.
(e) The term "placebo" is misleading "Placebo" suggests that only a placebo was given. In part A of the analysis placebo is the term used for "conventional" treatment and no details of this are given; however, 87% distinction between "no effect" and "negative effect" (or equivalently, "detrimental effect") is of no real importance. On the other hand, we would view it as unethical to continue such a trial in the face of a negative trend just to establish the distinction between "no effect" and "negative effect" beyond reasonable doubt. Decisions about the other treatments might have been different had a more detailed analysis been available to us.
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